{
    "clinical_study": {
        "@rank": "142753", 
        "arm_group": [
            {
                "arm_group_label": "No treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "patients with recurrent miscarriages"
            }, 
            {
                "arm_group_label": "OFFICE HYSTEROSCOPY", 
                "arm_group_type": "Active Comparator", 
                "description": "Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to evaluate the role of uterine natural killer cell(uNK)in recurrent\n      pregnancy losses and the correlation between the numbers of it and embryo toxicity by\n      measuring the level of the Th2 cytokines in normal reproductive profile and in patients with\n       Recurrent Pregnancy Losses (RPL)."
        }, 
        "brief_title": "The Role of Uterine NK Cells and T Cell Cytokines in Recurrent Miscarriage", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Recurrent Pregnancy Losses", 
        "condition_browse": {
            "mesh_term": [
                "Abortion, Spontaneous", 
                "Abortion, Habitual"
            ]
        }, 
        "detailed_description": {
            "textblock": "Office hysteroscopy examination of the patients at the luteal phase of the natural cycle\n      (day17 to day 20),with endometrial biopsy using pipple curette from the region of the\n      fundus, the biopsy sent to flow cytometry laboratory in South Egypt Cancer Institute to be\n      examined for:\n\n      1.1. Phenotypic analysis of uterine natural killer cells:\n\n      1.2.  Induction and detection of intracellular cytokines by flow Cytometry:"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Women with unexplained recurrent miscarriages (2 or more consecutive).\n\n          2. All patients have normal uterine cavity diagnosed by HSG and /or hysteroscopy, normal\n             semen analysis, normal thrombophilic profiles, no history of malformed\n\n          3. normal fetus in the previous miscarriages\n\n        Exclusion Criteria:\n\n          1. Age above forty years old .\n\n          2. Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies [IgG\n             or IgM]); other recognised thrombophilic conditions (testing according to usual\n             clinic practice).\n\n          3. Intrauterine abnormalities (as assessed by ultrasound, hysterosonography,\n             hysterosalpingogram, or hysteroscopy).\n\n          4. Fibroids distorting uterine cavity .\n\n          5. Abnormal parental karyotype .\n\n          6. Other identifiable causes of recurrent miscarriages (tests initiated only if\n             clinically indicated) e.g., diabetes, thyroid disease and systemic lupus\n             erythematosus (SLE)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688284", 
            "org_study_id": "UNKTRPL"
        }, 
        "intervention": {
            "arm_group_label": [
                "No treatment", 
                "OFFICE HYSTEROSCOPY"
            ], 
            "description": "Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome", 
            "intervention_name": "office hysteroscopy", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "uterine natural killer cells", 
            "recurrent miscarriages", 
            "alloimmunity"
        ], 
        "lastchanged_date": "September 18, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Assiut", 
                    "country": "Egypt"
                }, 
                "name": "Women Health Hospital"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Uterine NK Cells and T Cell Cytokines in Recurrent Miscarriage.", 
        "overall_official": {
            "affiliation": "women health hospital,assiut university,egypt", 
            "last_name": "Alaa M Ismail, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Egypt: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "the role of uterine natural killer cell(uNK)in recurrent pregnancy losses and the correlation between the numbers of it and embryo toxicity by measuring the level of the Th2 cytokines in normal reproductive profile and in patients with RPL.", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688284"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Woman's Health University Hospital, Egypt", 
            "investigator_full_name": "alaa eldeen mahmoud ismail", 
            "investigator_title": "Assistant professor ob/gyn,specialest of infertility and fetal medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "to set in the horizon the role of immunomodulators as a treatment for RPL and implantation failure", 
            "safety_issue": "Yes", 
            "time_frame": "two years"
        }, 
        "source": "Woman's Health University Hospital, Egypt", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Woman's Health University Hospital, Egypt", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}